<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943110</url>
  </required_header>
  <id_info>
    <org_study_id>HS 720</org_study_id>
    <nct_id>NCT01943110</nct_id>
  </id_info>
  <brief_title>Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.</brief_title>
  <official_title>A Clinical Trial to Evaluate the Performance and Safety of Two Intradermal Delivery Devices.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SID Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether two intradermal (ID) vaccine delivery
      devices can safely and precisely inject liquid into the intradermal layer of the skin in
      three different injection locations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a preliminary device safety and performance evaluation in healthy adult
      volunteers (ages 18-55 years).

      Each participant will receive six injections of 0.1 ml of sterile saline solution into the
      skin:

        -  Upper deltoid with the side-load ID adapter

        -  Upper deltoid with the autodisable (AD) ID adapter

        -  Suprascapular (behind the shoulder) with the side-load ID adapter

        -  Suprascapular with the AD ID adapter

        -  Forearm with the side-load ID adapter

        -  Forearm with the AD ID adapter

      Intradermal administration of each injection will be assessed:

        -  The liquid remaining on the surface of the skin will be blotted with absorbent paper and
           the amount of liquid present will be recorded.

        -  The formation of an intradermal wheal will be observed, and the diameter of the wheal
           measured using a ruler or similar measurement tool.

        -  A photo of the injection site will be taken.

      Injections will be assessed for safety by observation of injection sites for any local
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Injections Delivered to the Intradermal Layer of the Skin</measure>
    <time_frame>1 day</time_frame>
    <description>The proportion of saline injections resulting in delivery to the intradermal layer of the skin will be assessed by measurement of intradermal wheals with diameters â‰¥ 5mm and the volume of liquid injected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Injections With Safety Events</measure>
    <time_frame>Within 30 minutes and within 48 hours of injection</time_frame>
    <description>The proportion of injections with safety events will be calculated for events occurring within 30 minutes and within 48 hours of injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Injections, Intradermal</condition>
  <arm_group>
    <arm_group_label>Saline injection with ID adapters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:
Upper deltoid with the side-load ID adapter
Upper deltoid with the AD ID adapter
Suprascapular (behind the shoulder) with the side-load ID adapter
Suprascapular with the AD ID adapter
Forearm with the side-load ID adapter
Forearm with the AD ID adapter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ID adapter (autodisable)</intervention_name>
    <description>Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.</description>
    <arm_group_label>Saline injection with ID adapters</arm_group_label>
    <other_name>Autodisable intradermal adapter</other_name>
    <other_name>AD ID adapter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ID adapter (side load)</intervention_name>
    <description>Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.</description>
    <arm_group_label>Saline injection with ID adapters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male participants ages 18 to 55 years.

          -  Healthy enough to participate in the clinical trial per site investigator assessment.

          -  Healthy skin on the upper deltoid, suprascapular, and forearm regions (both sides of
             the body).

          -  Able to provide signed informed consent and understand study procedures per ICH/GCP
             guidelines.

          -  Literate in English.

          -  Available by telephone 48 hours after the study visit.

        Exclusion Criteria:

        - Skin abnormalities on upper deltoid, suprascapular, and forearm regions of either side of
        the body (scars, rash, infection), tattoo at the injection site, or other skin conditions
        that would interfere with the ability to visualize an intradermal injection in the opinion
        of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Klaff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://sites.path.org/vpdt/</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2015</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intradermal injections</keyword>
  <keyword>Vaccine delivery devices</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Injection With ID Adapters</title>
          <description>Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:
Upper deltoid with the side-load ID adapter
Upper deltoid with the AD ID adapter
Suprascapular (behind the shoulder) with the side-load ID adapter
Suprascapular with the AD ID adapter
Forearm with the side-load ID adapter
Forearm with the AD ID adapter
ID adapter (autodisable): Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
ID adapter (side load): Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy adults aged 18-55 years.</population>
      <group_list>
        <group group_id="B1">
          <title>Saline Injection With ID Adapters</title>
          <description>Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:
Upper deltoid with the side-load ID adapter
Upper deltoid with the AD ID adapter
Suprascapular (behind the shoulder) with the side-load ID adapter
Suprascapular with the AD ID adapter
Forearm with the side-load ID adapter
Forearm with the AD ID adapter
ID adapter (autodisable): Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
ID adapter (side load): Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="19" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Injections Delivered to the Intradermal Layer of the Skin</title>
        <description>The proportion of saline injections resulting in delivery to the intradermal layer of the skin will be assessed by measurement of intradermal wheals with diameters â‰¥ 5mm and the volume of liquid injected.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADID Deltoid</title>
            <description>Injections given with the autodisable ID adapter in the deltoid region</description>
          </group>
          <group group_id="O2">
            <title>ADID Forearm</title>
            <description>Injections given with the autodisable ID adapter in the forearm</description>
          </group>
          <group group_id="O3">
            <title>ADID Suprascapular</title>
            <description>Injections given with the autodisable ID adapter in the suprascapular region</description>
          </group>
          <group group_id="O4">
            <title>SLA Deltoid</title>
            <description>Injections given with the side-load ID adapter in the deltoid region</description>
          </group>
          <group group_id="O5">
            <title>SLA Forearm</title>
            <description>Injections given with the side-load ID adapter in the forearm</description>
          </group>
          <group group_id="O6">
            <title>SLA Suprascapular</title>
            <description>Injections given with the side-load ID adapter in the suprascapular region</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Injections Delivered to the Intradermal Layer of the Skin</title>
          <description>The proportion of saline injections resulting in delivery to the intradermal layer of the skin will be assessed by measurement of intradermal wheals with diameters â‰¥ 5mm and the volume of liquid injected.</description>
          <units>Injections</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Injections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wheal diameter &gt;=5mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leakage &lt;=10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Injections With Safety Events</title>
        <description>The proportion of injections with safety events will be calculated for events occurring within 30 minutes and within 48 hours of injection.</description>
        <time_frame>Within 30 minutes and within 48 hours of injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AD ID Adapter</title>
            <description>Injections given with the autodisable ID adapter</description>
          </group>
          <group group_id="O2">
            <title>SLA ID Adapter</title>
            <description>Injections given with the side-load ID adapter</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Injections With Safety Events</title>
          <description>The proportion of injections with safety events will be calculated for events occurring within 30 minutes and within 48 hours of injection.</description>
          <units>percentage of injections</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Injections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local AE at 30 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local AE at 2 days post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <desc>Certain signs and symptoms were pre-specified in the case report form for participants in the study. These included bleeding, redness, pain, bruising, and abrasion at the injection site. There was also space for recording other local or systemic AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>ADID Deltoid</title>
          <description>Injections given with the autodisable ID adapter in the deltoid region</description>
        </group>
        <group group_id="E2">
          <title>ADID Forearm</title>
          <description>Injections given with the autodisable ID adapter in the forearm region</description>
        </group>
        <group group_id="E3">
          <title>ADID Suprascapular</title>
          <description>Injections given with the autodisable ID adapter in the suprascapular region</description>
        </group>
        <group group_id="E4">
          <title>SLA Deltoid</title>
          <description>Injections given with the side-load ID adapter in the deltoid region</description>
        </group>
        <group group_id="E5">
          <title>SLA Forearm</title>
          <description>Injections given with the side-load ID adapter in the forearm region</description>
        </group>
        <group group_id="E6">
          <title>SLA Suprascapular</title>
          <description>Injections given with the side-load ID adapter in the suprascapular region</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic AE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local AE at injection site 30 minutes after injection</sub_title>
                <description>Local AEs reported included pain, redness, bruising, and abrasion. All were minor and resolved within 1 day following injections.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abrasion at injection site immediately after injection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Drop of blood at injection site immediately after injection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Local AEs at injection site 2 days after injection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor, funder, and PI of this study have jointly published the results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney Jarrahian</name_or_title>
      <organization>PATH</organization>
      <phone>206-285-3500</phone>
      <email>cjarrahian@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

